Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Acute T Cell Leukemia Clinical Trial

Official title: Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia

Status Not yet recruiting

Clinical Trial Summary

To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute lymphocytic leukemia (ETP-ALL). Once determined, the purpose of this study will be to determine the efficacy of ruxolitinib in combination with LVP in patients with R/R ETP-ALL.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Acute T Cell Leukemia
• Leukemia
• Leukemia, T-Cell
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

• NCT number: NCT03613428
• Study type: Interventional
• Source: Sichuan University
• Contact: Jie Ji, MD
• Phone: 86-18980605802
• Email: jieji@scu.edu.cn
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: December 1, 2018
• Completion date: March 30, 2021